Lei Zhang

FDA investigator

Appears on 4 documents from 2019 to 2025, most often at sites in Australia. Most often cites production record review (21 CFR 211.192).

4
Documents on file
5.0
Observations per 483
2019
First seen
2025
Most recent

What they cite most

From 20 observations

Activity by year

2019: 1, 2023: 1, 2024: 1, 2025: 1

Where

Australia 1 · Iceland 1 · Rhode Island 1 · Switzerland 1

Is Lei Zhang coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

4 documents, newest first
FirmOpen
483 Lonza AGOct 28, 2025 · Visp, Switzerland
483 CSL Behring (Australia) Pty LtdMar 8, 2024 · Broadmeadows, Australia
483 Alvotech HfMar 17, 2023 · Reykjavik, Iceland
483 Immunex Rhode Island CorporationApr 19, 2019 · West Greenwich, Rhode Island

About this profile

What does Lei Zhang inspect?

Lei Zhang appears on 4 documents on file covering 4 sites, most often in Australia.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.68 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Lei Zhang is dated Oct 28, 2025.